The product has been approved by Drug Controller General of India (DCGI) and is recommended as a first-line treatment for mCRC, Hetero said in a statement.
“It has been an exciting journey for us in biologics. Hetero’s Bevacizumab is the third product in our biologics portfolio, after Darbepoetin alfa and Rituximab. We believe CizumabTM will be a cost-effective treatment option to patients,” Hetero Group of Companies CMD BPS Reddy said.
The product will be made available to patients in a single dose vial with two strengths, 100 mg and 400 mg, the company said.
It will be marketed and distributed by Hetero Healthcare Limited, a group company of Hetero.
Hyderabad-based Hetero is one of the world’s largest producer of anti-retroviral drugs for the treatment of HIV/AIDS.
(This story has not been edited by NDTV staff and is auto-generated from a syndicated feed.)